News
ARCT
26.61
-3.74%
-1.04
As more rare disease therapies launch, their prices are rising
Therapies that treat rare diseases are among the most expensive treatments for patients. The most expensive medicine in the world, Lenmeldy, comes with a wholesale price of $4.25M. Cantor Fitzgerald says the prices of rare disease therapies have been increasing since 2021.
Seeking Alpha · 2d ago
Weekly Report: what happened at ARCT last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at ARCT last week (0401-0405)?
Weekly Report · 04/08 12:05
Weekly Report: what happened at ARCT last week (0325-0329)?
Weekly Report · 04/01 12:02
Buy Rating Affirmed for Arcturus: Promising Vaccine Commercialization and Rare Disease Pipeline Progress
TipRanks · 04/01 11:15
Optimistic Buy Rating for Arcturus Therapeutics Amid Strong Kostaive Vaccine Market Prospects in Japan
TipRanks · 03/26 11:15
Weekly Report: what happened at ARCT last week (0318-0322)?
Weekly Report · 03/25 12:05
Analysts’ Top Healthcare Picks: Enliven Therapeutics (ELVN), Alphatec Holdings (ATEC)
3 analysts have maintained Buy ratings on Enliven Therapeutics, Alphatec Holdings and Arcturus Therapeutic. The 3 stocks are in the Healthcare sector and are expected to make moves following their insider activities. The analyst consensus for each of the 3 stocks is a strong Buy.
TipRanks · 03/20 11:30
Arcturus Therapeutics’ Kostaive® Vaccine Succeeds in Phase III
Meiji Holdings has announced the success of the Kostaive® bivalent mRNA COVID-19 vaccine in a Phase III clinical trial for booster vaccination in Japan. This comes after a distribution agreement with influenza vaccine leader Seqirus for the vaccine’s sales in Japan .
TipRanks · 03/19 10:12
Monday's ETF Movers: VOX, XBI
NASDAQ · 03/18 16:03
Weekly Report: what happened at ARCT last week (0311-0315)?
Weekly Report · 03/18 12:03
Arcturus Therapeutics Price Target Raised to $87.00/Share From $81.00 by Canaccord Genuity
Dow Jones · 03/11 12:02
Arcturus Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 03/11 12:02
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on rare diseases. The company has a 12-month price target of $63.25. In the past three months, 4 analysts have released ratings for ArcturusTherapeutics. The firm has an average price target for the company of $87.00.
Benzinga · 03/11 12:01
Weekly Report: what happened at ARCT last week (0304-0308)?
Weekly Report · 03/11 11:59
Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Raises Price Target to $87
Benzinga · 03/11 11:51
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)
Companies in the Healthcare sector have received a lot of coverage today. Applied Therapeutics, Xeris Pharmaceuticals and Arcturus Therapeutic have been recommended by analysts. Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on AppliedTherapeutics. The company has an analyst consensus of Strong Buy for the stock.
TipRanks · 03/11 04:40
Arcturus Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Dow Jones · 03/08 14:52
HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $60 Price Target
Benzinga · 03/08 14:42
Arcturus Therapeutics Is Maintained at Overweight by Wells Fargo
Dow Jones · 03/08 13:00
More
Webull provides a variety of real-time ARCT stock news. You can receive the latest news about Arcturus Therape through multiple platforms. This information may help you make smarter investment decisions.
About ARCT
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.